Bill Rich — the man who built a company around SELDI mass spec technology — does not care about mass specs. He also doesn’t care about protein sequencing, large core proteomics facilities, analytical chemists, or “third decimal point accuracy” resolution. So what does the CEO of Ciphergen, the company that pioneered the booming bio-marker market, care about?
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.